Beyond the well-known cannabinoids of THC and CBD, there’s a whole world of rare cannabinoids. Indeed, there are more than 100 rare cannabinoids that have been found in the Cannabis plant, including CBG, CBN, CBC and THCV with unique properties that are believed to have a wide range of health benefits. However, these ‘minor’ or ‘rare cannabinoids’ are present in much smaller quantities in the plant and therefore have not been studied extensively due to limited access. As a result the pharmaceutical and consumer applications of these cannabinoids are only beginning to be understood. In addition, the very low levels in the plant have also made it economically impractical to extract for any large-scale commercial purposes. For this reason, much like many other products we use in our daily lives, it is necessary to evolve into synthetic approaches to produce the raw materials used in these products. There are a few manufacturing processes that are widely used, including chemical synthesis and biosynthesis. Recent reports suggest the biosynthesis of rare cannabinoids could be a $10B market by 2025 increasing to $115B in 2040. At the end of the day, companies that produce rare cannabinoids with the highest quality and lowest prices will emerge as real leaders as this market evolves. This is where InMed Pharmaceuticals Inc. (Nasdaq: INM), a manufacturer and clinical developer of rare cannabinoids, is now stepping into a leadership role with their organic & acquisitive developments.
What quality controls should be put in place to ensure consistency and purity of cannabinoids for CPG products?
Dr. Shane Johnson, GM of BayMedica, InMed’s subsidiary, answers these questions: What is the minimum GMP standard that consumers should expect? What quality controls should
August 18, 2023
